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Summary The effects of treatment with 5-FU/folinic acid on interleukin-2 related lymphocyte responses was
investigated in 21 patients with advanced colorectal cancer. The treatment was not suppressive of IL-2 related
lymphocyte responses. Furthermore, at certain time points in the treatment cycles the capacity to generate
lymphokine-activated killer (LAK) cells from the peripheral blood mononuclear cells of these patients was
significantly augmented above that observed prior to treatment. These results provide a logical basis for the
design of regimens which combine two approaches, each of low individual therapeutic efficacy, to treat
patients with advanced colorectal cancer in the hope of increasing clinical response rates.
Cancer therapy with the recombinant lymphokine interleu-
kin-2 (IL-2) is based on the in vivo activation of lymphokine-
activated killer (LAK) cells and/or tumour-infiltrating cyto-
toxic T-lymphocytes (TIL) which can directly lyse tumour
cells, although they may also act via other as yet ill-defined
mechanisms. IL-2 therapy is finding a limited role in the
treatment of patients with advanced malignant melanoma
and renal cell cancer for which no suitable alternative chemo-
therapy has been discovered (Rosenberg et al., 1989). Unfor-
tunately, for patients with colorectal cancer neither IL-2
therapy nor chemotherapy with 5-fluorouracil (5-FU) alone
appear to have a significant impact on disease progression
and survival in more than 10-15% of patients, although
combinations of 5-FU with folinic acid appear to provide
greater response rates than does 5-FU alone (reviewed by
Arbuck, 1989).
Because few alternative treatment combinations exist for
the common metastatic malignancies, a number of workers
have explored the potential of combining chemotherapy with
immunotherapy in a variety of experimental models and
clinical scenarios. (North, 1982, Ades et al., 1987; Papa et al.,
1988; Eggermont & Sugarbaker, 1988; Lindemann et al.,
1989; Stoter et al., 1989). In the case of advanced colorectal
cancer a number of empirically-designed clinical protocols
combining 5-FU with IL-2 are being pursued (Hamblin et al.,
1989; C. Franks, personal communication). It is often
assumed that most clinically effective chemotherapy regimens
have immunosuppressive effects (Kempf & Mitchell, 1984;
Powell et al., 1990). Thus their combination with such agents
as IL-2 may at first sight be illogical because some types of
immunosuppression diminish the efficacy of immunotherapy
(Vetto et al., 1987; Papa et al., 1986). To investigate this in
the context of colorectal cancer, we have examined the effects
of a chemotherapeutic regimen, considered to have some
clinical efficacy in colorectal cancer (Erlichman et al., 1988),
on natural killer (NK) cell activity, LAK cell induction,
T-cell proliferation and IL-2 production. Paradoxically,
rather than being immunosuppressive in this context, the use
of cycles of 5-FU/folinic acid appears to augment these
responses. These findings may provide a logical basis for the
design of clinical chemo-immunotherapeutic protocols in hu-
mans suffering from colorectal cancer.
Patients and methods
Patients and details oftreatment
These investigations were conducted in 21 consecutive pa-
tients referred to this unit for consideration for liver resection
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for liver metastases (n = 14) or 'second-look' surgery for
locally recurrent (n = 7) colorectal cancer but who were
found, on detailed investigation, to be unsuitable for further
resectional surgery. All had undergone previous resection of
their primary lesion between 3 and 38 months prior to refer-
ral. There were eight females and 13 males with a mean age
of 60.7 ± 9.4 ( ± s.d.) years (range 46-79 years). All were
symptomatic from their disease, had a WHO performance
index of 0 or 1, and had requested further treatment. Treat-
ment consisted of 5-FU plus folinic acid administered accor-
ding to the regimen described by Doroshow et al. (1987).
Briefly, high-dose folinic acid (500 mg -2 day-') was given by
continuous infusion for 6 days and 5-FU at a dose of
370 mg m-2 by intravenous push daily for 5 days commenc-
ing 24 h after the start of the folinic acid infusion. This was
repeated at 28-day intervals for two cycles following which
the patients were evaluated for disease stability, disease pro-
gression or radiological response at 56 days after initiating
therapy. All 21 patients received two cycles of therapy but no
further treatment was administered to patients with progres-
sive disease whereas therapy was continued monthly for a
further 4 months in those with stable disease (no change in
size of measurable lesion) or in whom there was radiological
evidence of a partial tumour response. Tumour response was
defined as a reduction of greater than 50% or more in the
product of two measurable diameters of a preselected,
defined indicator lesion. According to this definition 12
patients had progressive disease and ceased therapy after 2
months. Of the remaining nine patients, four had static
disease (three with liver metastases and one with local recur-
rence) which remained static for 3, 4, 5 and 6 months respec-
tively. Five patients had radiological evidence of reduction in
the dimensions of their indicator lesions (one with local
recurrence and four with liver metastases) and these re-
sponses have been maintained for 6, 5, > 12, > 12 and > 12
months respectively. No complete responses (disappearance
of all radiological lesions) have been observed. All but two of
the patients with evidence of static or diminishing disease are
currently alive between 6 and 14 months after initiation of
therapy. All the patients whose disease progressed
radiologically died with 7 months of starting therapy.
Immunological assays
These were performed on peripheral blood mononuclear cells
(PBMC) isolated on Ficoll-Hypaque gradients from hepar-
inised samples of peripheral venous blood obtained at the
same time on each day. The natural killer (NK) cell activity
of these PBMC was quantified by a standard 4 h "'Cr-release
assay as previously described (Monson et al., 1987) using the
K562 erythroleukaemic cell line as an NK-sensitive target
cell, or, for the quantification of spontaneous lymphocy-
totoxicity against an NK-resistant target, the colorectal can-
cer cell line, COL0205. Lymphokine-activated killer (LAK)
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cells were also generated from these PBMC by a previously
reported method (Guillou et al., 1989). Briefly 107 PBMC
were cultured in 10 ml volumes of RPMI medium containing
10% fetal calf serum in the presence of 1,000 units ml-' of
recombinant interleukin-2 (IL-2) (kindly provided by Euro-
Cetus Ltd) for a period of 4 days. The activated lymphocytes
recovered at the end of this period were then utilised as
effector cells in a 4 h 5'Cr-release assay against the NK-
resistant DAUDI and COLO205 cell lines. On occasions
when there were insufficient cells available to perform LAK
assays against both targets, the cytotoxicity assay against
COLO205 was omitted. NK and LAK assays were conducted
at effector:target ratios ranging from 50:1 to 6.25:1. The
percentage specific 5'Cr released at each effector:target cell
ratio was calculated according to the usual formula as fol-
lows:
% Specific 51Cr released=
experimental 5"Cr-release - spontaneous 5'Cr-release 1 maximum 5"Cr-incorporated - spontaneous 51Cr-release x 00
where spontaneous 5'Cr-release is that obtained from a 4h
incubation of 103 target cells alone, and maximum 5'Cr-
release is that which is released following treatment of 103
target cells with a detergent solution. In these studies the
ratio of spontaneous to maximum 5"Cr-release never exceeded
15%. The specific 5'Cr-release data were then converted to
lytic units defined as the number of cells per 107 lymphocytes
required to cause 30% specific 5'Cr-release from the tumour
target cell in question.
Unfractionated PBMC from these patients were also acti-
vated with concanavalin A (Con A) to quantify the effects of
therapy on lymphocyte proliferation and IL-2 production.
105 cells per well in 0.2 ml RPMI/10% FCS were cultured in
quadruplicate in 96-well flat-bottomed microtitre plates
(Nunc, Gibco Ltd, UK) in the presence of I0Og ml-' of Con
A (Sigma, UK). Quadruplicate control wells containing no
Con A were also prepared. The microplates were incubated
for 24 h in 5% CO2 in humidified air following which 100ttl
supernatant was carefully withdrawn from each Con A
activated well, pooled and stored at - 20°C for subsequent
IL-2 assay. A similar volume was discarded from each of the
unstimulated wells, and in all wells this was replaced by
100fsl medium containing 0.1I Ci of 3H-thymidine. Culture
was continued for a further 16 h. The cells were harvested
onto glass fibre discs using an automatic cell harvester
(Dynatech, UK). The amount of 3H-thymidine incorporated
was measured by beta counting and the data expressed as a
stimulation index calculated as
SI mean c.p.m. in stimulated cultures mean c.p.m. in unstimulated cultures
IL-2 assay
The IL-2 content of supernatants from lectin-activated lym-
phocytes was measured by the bioassay described by Gillis et
al. (1987) using the IL-2 dependent cloned murine CTLL-2
cell line as an indicator cell. These were cultured in 96-well
flat bottomed microtitre trays at a concentration of 4 x 103
cells per well in the presence of doubling dilutions of super-
natants derived from the Con A-activated peripheral blood
mononuclear cells. The cultures were incubated for 24 h at
37°C in a humidified atmosphere of 5% CO2 in air, pulsed
with 0.1I Ci 3H-thymidine per well for 6 h, and then har-
vested for beta counting as described above. Each assay
included doubling dilutions of a standard recombinant IL-2
preparation containing 100 Cetus units of IL-2 ml-' and the
amount of IL-2 present in the supernatant in question was
then calculated by probit analysis as previously described
(Monson et al., 1986).
Statistical analyses
For ease of presentation and analysis, data from the 5'Cr-
release assays was converted into log,0 lytic units. For the
purposes of graphic presentation all lymphocytotoxicity data
have been expressed as the mean ± the standard deviation of
the mean logl0 lytic units. However, all statistical analyses
were conducted using the non-parametric Mann-Whitney U
test because even after logarithmic transformation the data
were not parametric and it was not always feasible to per-
form every assay on every patient at every time point.
Results
Lymphocytotoxicity assays
The changes occurring in NK activity during the course of
treatment with 5-FU/folinic acid in these patients are shown
in Figure 1. Note that the Y-axis is expressed as logl0 lytic
units and so a relatively small apparent change represents a
considerable actual change. Although there is a trend to-
wards an increase in NK activity in the 4th and 5th weeks
after the initiation of therapy compared with pre-treatment
values, none of these changes was statistically significant. No
spontaneous lymphocytotoxicity against the NK-resistant cell
line COL0205 was observed.
In contrast, highly significant changes were observed in the
capacity to generate LAK cells from the PBMC of these
patients. The data from studies in which the international
reference target for LAK cells, the DAUDI cell line was used
as a LAK cell target are shown in Figure 2, where again the
data are expressed in log,0 lytic units but on a rather more
contracted vertical scale than those data shown in Figure 1.
It can be seen that at the end of the first cycle of therapy
(day 28) there was a statistically significant increase in the
capacity to generate LAK cells from the peripheral blood
mononuclear cells of these patients (U = 109.5, P = 0.05) and
which was already evident on day 14 after the initiation of
therapy (U = 67, P = 0.015). Furthermore, on measuring
LAK generation 2 days following the administration of the
next cycle of therapy (i.e. on day 35 following initiation of
therapy) there was a further rise in LAK generation which
was again significantly greater than that seen prior to treat-
ment (U = 8, P = 0.005) and also significantly higher than
that seen at the end of the first month of therapy on day 28
(U = 19, P = 0.049). Thereafter, LAK cell generation pro-
gressively declined although on day 56 of the treatment it still
remained significantly higher than that seen on day 0
(U = 50, P = 0.036). By the 12th week after initiation of
treatment, LAK cell generation was not significantly different
from that seen prior to treatment (U = 20, P = 0.14), al-
though the numbers of patients available for study at this
stage were smaller, 12 patients having been withdrawn from
therapy.
A similar trend was observed when the COL0205 cell line
was employed as a LAK cell target (Figure 3). Compared
with pre-treatment figures, LAK cell generation was
significantly higher on days 14 (U = 74, P = 0.029), 28
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Figure 1 Changes observed in Natural killer cell activity during
chemotherapy with 5-FU/folinic acid. Data are expressed as
mean log lytic units ± s.d. Bold horizontal arrows denote periods
of infusion of 5-FU/folinic acid.
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Figure 2 Changes observed in the capacity to generate Lympho-
kine-activated killer cells from the peripheral blood mononuclear
cells of patients with colorectal cancer during therapy with 5-FU/
folinic acid. Target cell, DAUDI. Otherwise legend as for Figure
1.
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Figure 4 Changes in lectin (Con A)-induced lymphocyte pro-
liferation in patients with colorectal cancer during chemotherapy
with 5-FU/folinic acid. Data expressed as mean stimulation
index ± s.d.
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Figure 3 Legend as for Figure 2 except that the data shown are
those obtained using the COL0205 cell line as a target in the
LAK cell assay.
(U = 104.5, P = 0.024) and 56 (U = 34.5, P = 0.012), al-
though by day 84 the apparently higher LAK cell generation
seen in these patients at this point did not reach statistical
significance (U = 16.5, P = 0.077).
The mean loglo LAK activity induced against DAUDI cells
at 1 and 2 months of therapy in patients who either had
responded or had stable disease (n = 9) was higher than that
of lymphocytes obtained from those with progressive disease
(n = 12), although this did not achieve statistical significance
(3.33 1.2 vs 2.58 ± 0.79, P=0.18 at 28 days and
3.14 1.07 vs 2.35 ± 0.19, P = 0.08 at 56 days). A similar
trend was seen when LAK activity against the COL0205 cell
line was compared at these two time points (2.7 ± 0.16 vs
2.33+0.52, P=0.18 at 28 days and 3.5±0.9 vs 2.4+0.65,
P = 0.08 at 56 days).
Lectin-induced lymphocyte proliferation
The pattern of change in lectin (Con A)-induced lymphocyte
proliferation during this therapy are shown in Figure 4. No
significant changes were observed until the 28th day after the
initiation of treatment (i.e. just prior to the administration of
the second cycle of 5-FU/folinic acid), when the mean stim-
ulation index was significantly higher than that observed
prior to therapy (U = 78, P = 0.042). The stimulation index
then appeared to fall immediately following the second cycle
of treatment although it did not descend below baseline
values. Thereafter the mean stimulation index rose progres-
sively and just prior to the third infusion cycle was again
significantly higher than that seen prior to therapy (U = 18,
P = 0.02) and also was significantly higher than that seen on
day 35 (U = 25, P = 0.04). Data obtained subsequent to day
56 of treatment were too small for statistical analysis to be
valid.
IL-2production
The production of IL-2 by Con-A-activated lymphocytes
during 5-FU/folinic acid therapy is shown in Figure 5. There
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Figure 5 Interleukin-2 production by lectin-activated lympho-
cytes from patients with colorectal cancer during chemotherapy
with 5-FU/folinic acid. Data are expressed as mean IL-2 produc-
tion ± s.d.
was no diminution of IL-2 production at any stage through-
out the period of treatment although the numbers of avail-
able lymphocytes for these and all the other assays became
attenuated during the second and third cycles of therapy.
Nevertheless, by day 28 the amount of biologically active
IL-2 in the supernatants of Con A-activated peripheral blood
mononuclear cells from these patients was significantly higher
than that measured under the same conditions prior to the
initiation of therapy (U = 24, P= 0.046). By day 56 the
supernatant IL-2 content was not significantly different from
that of supernatants from cells obtained prior to treatment
(U = 18, P = 0.093). Again, data obtained beyond day 56 of
the treatment cycle was inadequate for statistical analysis.
Lymphocyte:monocyte ratios before and during treatment
The mean lymphocyte:monocyte ratio in the peripheral blood
before the initiation of therapy was 2.65:1. At 28 days of
therapy it was 2.26: 1 and after 56 days of treatment it was
2.5:1. Neither of these ratios was significantly different from
that observed prior to treatment.
Discussion
We were motivated to conduct this investigation because of
the current vogue for the design of therapeutic protocols
which combine chemotherapy with IL-2 for the treatment of
refractory solid tumours. Some of these protocols, such as
those which involve pre-treatment with cyclophosphamide
(CY), have undergone extensive pre-clinical study and have a
sound scientific basis. Thus, CY attenuates the toxicity of
IL-2 in mice, and exerts a synergistic therapeutic effect with
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IL-2 on relatively IL-2 resistant tumours in rodents (Papa et
al., 1988; Rosenstein et al., 1986). This combination may
have some merit when applied clinically (Mitchell et al.,
1988).
However, other protocols have been introduced on an
empirical basis without prior study of the influence which the
chemotherapeutic agent has on the desirable immunological
events induced by IL-2 (Stoter et al., 1989; Flaherty, 1989).
Before embarking on the design of a chemo-immunothera-
peutic protocol which involved the combination of IL-2 with
5-FU in patients with colorectal cancer, we wished to deter-
mine the influence on IL-2-based responses of a 5-FU regi-
men with demonstrable therapeutic efficacy. Currently this is
considered to be best achieved by combining 5-FU with
folinic acid (Erlichman et al., 1988; Kerr, 1989). We antic-
ipated that lymphocyte responses to cytokine activation
would be diminished following an infusion of folinic acid
accompanied by intravenous bolus 5-FU for 5 days. How-
ever, this combination proved not to be immunosuppressive
and was followed by an augmented capacity to generate
LAK cells from the peripheral blood lymphocytes of patients
within the first month of initiating treatment. After the first
month of therapy, wide individual variations in the capacity
to generate LAK cells from the lymphocytes of these patients
were observed but the augmented responses were maintained
through second and third cycles of treatment although the
magnitude of the subsequent changes appeared less marked
than those observed through the first cycle of treatment
(Figure 2).
In considering the mechanism of this augmented LAK
induction following 5-FU/folinic acid treatment it is impor-
tant to note that this occurred without any significant in-
crease of similar magnitude in NK activity. Classical NK
cells with the CD3-, CD16+, CD56+ phenotype are con-
sidered to represent the principal precursor lymphocyte pop-
ulation from which LAK cells are derived on exposure to
IL-2 (Herberman et al., 1987). These data would therefore
suggest that the capacity for augmented LAK cell induction
seen following this treatment is due to an increase in the
sensitivity of LAK precursors to activation with IL-2 rather
than to an increase in the circulating NK-derived precursor
pool. In this context our data bear some similarities with
those described by Arinaga et al. (1986) following a single
intravenous dose of Adriamycin, and Kiyohara et al. (1988)
during intensive polychemotherapy for urinary tract cancer.
However, NK cells are not the sole source of precursors for
the generation of non-MHC-restricted lymphocytotoxicity.
For example, CD3+ T-cells which possess the 1/6 T-cell
receptor have been found to exert non-restricted tumour cell
lysis on exposure to IL-2 in vitro (Borst et al., 1987) and
expansion of this small component ofperipheral blood CD3+
lymphocytes cannot be excluded from the present results. We
are currently conducting flow cytometric studies to determine
what, if any, phenotypic changes underlie these observations
because of the different receptor-ligand interactions which
direct allospecific and NK-associated cellular cytotoxicity
exerted by T-cells (Koide et al., 1989).
The immunological changes which occur following in-
travenously administered 5-FU/folinic acid do not appear to
be limited to MHC-unrestricted cellular cytotoxicity. In these
preliminary studies we have also found lectin-induced lym-
phocyte proliferation and IL-2 released from these activated
T-cells to be increased, at least within the first month of
therapy. Thereafter the changes are rather more erratic and
difficult to interpret, possibly because fewer patients were
available for study as patients with progressive disease were
withdrawn from treatment. Nevertheless, these results suggest
that the effects of this 5-FU/folinic acid regimen on the
immune system may be generalised and not simply restricted
to lymphocytotoxic precursors although we have not meas-
ured LAK precursor activity in patients after cessation of
therapy to determine whether LAK induction fell to pre-
treatment values.
Accepting the difficulties inherent in comparing cytotox-
icity data from one laboratory to another, the magnitude of
change in LAK precursor availability we have observed fol-
lowing 5-FU/folinic acid therapy is at least comparable to
that reported during the immediate 1 to 2 days of rebound
lymphocytosis following therapy with IL-2 alone. It has been
suggested that the magnitude of this rebound lymphocytosis,
though not the level of inducible cytotoxicity, correlates with
clinical response (West et al., 1987; Boldt et al., 1988). Others
have suggested that a high level of IL-2-primed LAK precur-
sors occurs during the post-IL-2 rebound and is responsible
for the response if further IL-2 is administered (Schoof et al.,
1988). Whatever the mechanism of the changes we describe,
the clinical implications of these data are that at the very
worst this therapeutic combination does not impair the
development of the cellular cytotoxic responses which under-
lie IL-2 therapy and may promote them. On the basis of the
results obtained from this study, such a regimen should
administer 5-FU/folinic acid first, followed by IL-2 14 days
later when there is an enhanced capacity for circulating LAK
cell precursors to generate a cytolytic response. These data
therefore provide a logical basis upon which to combine
these two different therapeutic approaches in the hope of
increasing clinical response rates in the treatment of unresec-
table colorectal cancer.
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